Background. Several studies demonstrated superiority of drug-eluting stents compared to bare metal stents in relative simple lesions and patients.Aim. The aim of the study was to analyze the results of paclitaxel eluting stents in patients with complicated lesions or in diabetics and to compare with bear metal stent patients having similar characteristics. Patients were selected from the randomized TAXUS II study. Methods. The TAXUS II study was a randomized, prospective study in 536 patients evaluating immediate and 12 months results in patients implanted with slow and moderate release paclitaxel stent with versus bare metal stent. From the baseline population, the subgroups of patients with complicated lesion were selected as follows (Taxus vs Controls): diabetics (32 vs 40 patients), female (68 vs 59 pts) small vessel of <2.75mm (130 vs 145), lesion length of >10 mm (130 vs 140), multiple stents (14 vs 19), or use of GP IIb/IIIa inhibitors (41 vs 47 pts). Results were expressed as a target lesion revascularization (TLR) rate at a follow-up time of 12 months. Results. 
Overall there was a 75% improvement for paclitaxel group compared to the bear metal stent group. Conclusions. The paclitaxel stent has proven its superiority over bear metal stent in terms of TLR at one year even in patients with complicated lesions, such as small vessel, long lesions or diabetics.
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